{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:22:33Z","timestamp":1793992953602,"version":"4.8.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jcyt.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T01:23:31Z","timestamp":1714872211000},"page":"1163-1169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Allogeneic transplantation after immunotherapy for relapsed\/refractory non-Hodgkin lymphoma: a comparison with a historical cohort"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-9296","authenticated-orcid":false,"given":"Jacopo","family":"Mariotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8529-6490","authenticated-orcid":false,"given":"Cristina","family":"Zucchinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"De Philippis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Mannina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Sarina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Taurino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Carbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcyt.2024.05.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100825","article-title":"Emerging new cell therapies\/immune therapies in B-cell non-Hodgkin's lymphoma","volume":"46","author":"Banerjee","year":"2022","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"10.1016\/j.jcyt.2024.05.002_bib0002","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jcyt.2024.05.002_bib0003","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T Cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.jcyt.2024.05.002_bib0004","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jcyt.2024.05.002_bib0005","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-Cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jcyt.2024.05.002_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"33","key":"10.1016\/j.jcyt.2024.05.002_bib0007","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1200\/JCO.19.01492","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study","volume":"37","author":"Zinzani","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jcyt.2024.05.002_bib0008","first-page":"2780","article-title":"Nivolumab combined with brentuximab vedotin for relapsed\/refractory mediastinal gray zone lymphoma","volume":"141","author":"Santoro","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2024.05.002_bib0009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jcyt.2024.05.002_bib0010","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jcyt.2024.05.002_bib0011","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0012","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience","volume":"143","author":"Rezvani","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jcyt.2024.05.002_bib0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0016","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0017","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/ijms24021045","article-title":"Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms?","volume":"24","author":"Martino","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0018","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/14737140.2021.1988853","article-title":"Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma","volume":"21","author":"Ahmed","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jcyt.2024.05.002_bib0020","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0021","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41409-022-01874-5","article-title":"EASIX predicts non-relapse mortality after haploidentical transplantation with post-transplant cyclophosphamide","volume":"58","author":"Mariotti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0022","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0023","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jcyt.2024.05.002_bib0024","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0025","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0026","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jcyt.2024.05.002_bib0027","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0028","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Non-parametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0029","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0030","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0031","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0032","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gammadependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0033","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0034","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"10.1016\/j.jcyt.2024.05.002_bib0035","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0036","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0038","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41409-023-02069-2","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas","volume":"58","author":"Pe\u00f1a","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0040","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0041","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"GEM (Grupo Espa\u00f1ol de Mieloma)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Group Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA\/GEM Clinical Trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0042","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0043","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3324\/haematol.11185","article-title":"Allogeneic transplantation in lymphoma: current status","volume":"92","author":"Schmitz","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0044","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0045","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0046","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/bloodadvances.2023010016","article-title":"Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions","volume":"7","author":"Major","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0047","doi-asserted-by":"crossref","first-page":"574.e1","DOI":"10.1016\/j.jtct.2023.06.019","article-title":"Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure","volume":"29","author":"Holland","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.7550","article-title":"Glofitamab monotherapy in pts with relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study","volume":"41","author":"Falchi","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0049","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.19057","article-title":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","volume":"204","author":"Dodero","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0050","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jtct.2022.05.043","article-title":"ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0051","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","article-title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","volume":"3","author":"Shadman","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.05.002_bib0052","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007060?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924007060?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:10:38Z","timestamp":1745323838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924007060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1465324924007060"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.002","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic transplantation after immunotherapy for relapsed\/refractory non-Hodgkin lymphoma: a comparison with a historical cohort","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}